Inovia Pharmaceuticals will move its hepatitis C DNA vaccine into a phase 1/11a clinical trial by the end of 2013. The advancement of this work is based on exceptional results of a preclinical study, which showed for the first time that a ...
Tags: Inovia Pharmaceuticals, hepatitis C DNA vaccine, clinical trial, 2013
Shire, a specialty biopharmaceutical company, is set to purchase US-based biotechnology company Lotus Tissue Repair. Under the purchase, Lotus Tissue Repair's intravenous protein replacement therapy, which is in late pre-clinical ...
Tags: Shire, biopharmaceutical company, US, Lotus Tissue Repair
Priaxon has signed research collaboration with GlaxoSmithKline (GSK) to develop small molecule modulators for various protein-protein-interactions (PPIs). The collaboration will utilize Priaxon's small molecule drug discovery knowledge in ...
Tags: Priaxon, GSK, drug discovery, clinical development, therapeutic areas
EMD Millipore, the life science division of Merck KGaA has introduced the Mobius FlexRead solution, which boasts Smart Flexware Asemblies for tangential flow filtration. The system gives specialists the ability to switch from TFF to ...
Tags: EMD Millipore, Merck KGaA, life science, tangential flow filtration
Tranzyme Pharma has completed the chemistry-based drug discovery partnership and transferred the resulting compounds to Bristol-Myers Squibb to advance the development. The strategic collaboration leveraged Macrocyclic Template Chemistry, ...
Tags: Tranzyme Pharma, chemistry based drug, chemistry technology, company news
Repligen has announced a new licensing agreement with Pfizer in an effort to advance Repligen's spinal muscular atrophy (SMA) program. The work focuses on RG3039, which is a small molecule drug candidate in clinical development for the ...
Tags: Repligen, Pfizer, spinal muscular atrophy, Medicine
Global healthcare products provider Covidien has singed an agreement to acquire CV Ingenuity for undisclosed sum. The transaction is also expected to increase Covidien's research and development expenditures to fund the clinical ...
Tags: Global healthcare, Covidien, CV Ingenuity, DCB technology
FINOX Biotech has submitted the Marketing Authorisation Application (MAA) for its biosimilar recombinant Follicle Stimulating Hormone (r-FSH) BEMFOLA to the European Medicines Agency. The submission was based on a comprehensive clinical ...
Tags: FINOX Biotech, Marketing Authorisation Application, Medicines, healthcare
Nuron Biotech has secured $80m finance from HealthCare Royalty Partners to support the commercialization and expansion of its Meningitec, a recently acquired vaccine from Pfizer. Meningitec is an established commercial vaccine to prevent ...
Tags: Nuron Biotech, secured finance, vaccine, Meningitec, commercial vaccine
PharmaNet/i3, the inVentiv Health Clinical segment, is providing the first mobile application for bioanalytical assays. The mobile application enables clients to search the company's more than 1000 bioanalytical assays from an iPhone, ...
Tags: Bioanalytical Assays, Mobile Application, PharmaNet/i3, Medicine
The adverse side effects of some medications for hepatitis C can now be observed and studied in laboratory conditions, using petri dishes and test tubes, thanks to the development of a new method by US researchers. A team led by Craig ...
Tags: anti-HCV treatments, hepatitis, disease, PLOS Pathogens
Braeburn, a subsidiary of Apple Tree Partners, has gained commercialization rights to Titan Pharmaceuticals' long-acting subdermal implant in the US and Canada, under the signed license agreement. The investigational subcutaneous implant, ...
Tags: Braeburn, Marketing Rights, subsidiary of Apple Tree Partners, Medicine
GlaxoSmithKline (GSK) has announced the FDA approval of four-strain seasonal influenza (flu) virus vaccine, Fluarix Quadrivalent, to immunize adults and children of three years age and more, in the US. The intramuscular vaccine is ...
US medical center, Mayo Clinic, has signed a pre-clinical research agreement with MagForce. Under the agreement, Mayo Clinic will begin a research program to investigate the preclinical efficacy of the MagForce's NanoTherm therapy in ...
Paragonix Technologies has won Phase I small business innovation research (SBIR) grant from the the National Heart, Blood and Lung Institute for the pre-clinical development of its Paragonix Sherpa cardiac transport system. Single-use, ...
Tags: Paragonix, SBIR grant, pre-clinical development, cardiac transport system